Improving cell and gene therapy safety and performance using next-generation Nanoplasmid vectors

The cell and gene therapy industry has employed the same plasmid technology for decades in vaccination, cell and gene therapy, and as a raw material in viral vector and RNA production. While canonical plasmids contain antibiotic resistance markers in bacterial backbones greater than 2,000 base pairs...

Descripción completa

Detalles Bibliográficos
Autores principales: Williams, James A., Paez, Patrick A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10280095/
https://www.ncbi.nlm.nih.gov/pubmed/37346980
http://dx.doi.org/10.1016/j.omtn.2023.04.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10280095/
https://www.ncbi.nlm.nih.gov/pubmed/37346980
http://dx.doi.org/10.1016/j.omtn.2023.04.003

Ejemplares similares